調査レポート | • レポートコード：QYR2104Z3407 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、128ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、リュープロリドのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（皮下、局所）、用途別市場規模（乳がん、子宮内膜症、思春期早発症、前立腺がん、子宮筋腫、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・リュープロリドの市場動向 ・企業の競争状況、市場シェア ・リュープロリドの種類別市場規模（皮下、局所） ・リュープロリドの用途別市場規模（乳がん、子宮内膜症、思春期早発症、前立腺がん、子宮筋腫、その他） ・リュープロリドの北米市場規模2016-2027（アメリカ、カナダ） ・リュープロリドのヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・リュープロリドのアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・リュープロリドの中南米市場規模2016-2027（メキシコ、ブラジル） ・リュープロリドの中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（TOLMAR PHARMACEUTICALS、Sanofi、Teva、Sandoz (Novartis)、Sun Pharmaceutical、AbbVie、Bayer、Takeda、Beijing Boente Pharmaceutical、Livzon Pharmaceutical、Selleck、Hangzhou Peptide Biochemical、Chengdu Shenguo Biological Pharmaceutical、SciAnda Pharma、Daewoong、GP Pharm、Enteris BioPharma、Chong Kun Dang、Leadiant Biosciences、Hikma Pharmaceuticals、Lee Pharma、Hanall） ・結論 |
Leuprolide belongs to the general class of drugs known as hormones or hormone antagonists. It is a synthetic 9 residue peptide analog of gonadotropin releasing hormone. Leuprolide is used to treat advanced prostate cancer. It is also used to treat uterine fibroids and endometriosis. Leuprolide is also under investigation for possible use in the treatment of mild to moderate Alzheimer’s disease.
Market Analysis and Insights: Global Leuprolide Market
The global Leuprolide market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Leuprolide market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Leuprolide market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Leuprolide market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Leuprolide market.
Global Leuprolide Scope and Market Size
Leuprolide market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Leuprolide market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Subcutaneous
Topical
Segment by Application
Breast Cancer
Endometriosis
Precocious Puberty
Prostate Cancer
Uterine Fibrosis
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
TOLMAR PHARMACEUTICALS
Sanofi
Teva
Sandoz (Novartis)
Sun Pharmaceutical
AbbVie
Bayer
Takeda
Beijing Boente Pharmaceutical
Livzon Pharmaceutical
Selleck
Hangzhou Peptide Biochemical
Chengdu Shenguo Biological Pharmaceutical
SciAnda Pharma
Daewoong
GP Pharm
Enteris BioPharma
Chong Kun Dang
Leadiant Biosciences
Hikma Pharmaceuticals
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Leuprolide Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Subcutaneous
1.2.3 Topical
1.3 Market by Application
1.3.1 Global Leuprolide Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Breast Cancer
1.3.3 Endometriosis
1.3.4 Precocious Puberty
1.3.5 Prostate Cancer
1.3.6 Uterine Fibrosis
1.3.7 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Leuprolide Market Perspective (2016-2027)
2.2 Leuprolide Growth Trends by Regions
2.2.1 Leuprolide Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Leuprolide Historic Market Share by Regions (2016-2021)
2.2.3 Leuprolide Forecasted Market Size by Regions (2022-2027)
2.3 Leuprolide Industry Dynamic
2.3.1 Leuprolide Market Trends
2.3.2 Leuprolide Market Drivers
2.3.3 Leuprolide Market Challenges
2.3.4 Leuprolide Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Leuprolide Players by Revenue
3.1.1 Global Top Leuprolide Players by Revenue (2016-2021)
3.1.2 Global Leuprolide Revenue Market Share by Players (2016-2021)
3.2 Global Leuprolide Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Leuprolide Revenue
3.4 Global Leuprolide Market Concentration Ratio
3.4.1 Global Leuprolide Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Leuprolide Revenue in 2020
3.5 Leuprolide Key Players Head office and Area Served
3.6 Key Players Leuprolide Product Solution and Service
3.7 Date of Enter into Leuprolide Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Leuprolide Breakdown Data by Type
4.1 Global Leuprolide Historic Market Size by Type (2016-2021)
4.2 Global Leuprolide Forecasted Market Size by Type (2022-2027)
5 Leuprolide Breakdown Data by Application
5.1 Global Leuprolide Historic Market Size by Application (2016-2021)
5.2 Global Leuprolide Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Leuprolide Market Size (2016-2027)
6.2 North America Leuprolide Market Size by Type
6.2.1 North America Leuprolide Market Size by Type (2016-2021)
6.2.2 North America Leuprolide Market Size by Type (2022-2027)
6.2.3 North America Leuprolide Market Size by Type (2016-2027)
6.3 North America Leuprolide Market Size by Application
6.3.1 North America Leuprolide Market Size by Application (2016-2021)
6.3.2 North America Leuprolide Market Size by Application (2022-2027)
6.3.3 North America Leuprolide Market Size by Application (2016-2027)
6.4 North America Leuprolide Market Size by Country
6.4.1 North America Leuprolide Market Size by Country (2016-2021)
6.4.2 North America Leuprolide Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Leuprolide Market Size (2016-2027)
7.2 Europe Leuprolide Market Size by Type
7.2.1 Europe Leuprolide Market Size by Type (2016-2021)
7.2.2 Europe Leuprolide Market Size by Type (2022-2027)
7.2.3 Europe Leuprolide Market Size by Type (2016-2027)
7.3 Europe Leuprolide Market Size by Application
7.3.1 Europe Leuprolide Market Size by Application (2016-2021)
7.3.2 Europe Leuprolide Market Size by Application (2022-2027)
7.3.3 Europe Leuprolide Market Size by Application (2016-2027)
7.4 Europe Leuprolide Market Size by Country
7.4.1 Europe Leuprolide Market Size by Country (2016-2021)
7.4.2 Europe Leuprolide Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Leuprolide Market Size (2016-2027)
8.2 Asia-Pacific Leuprolide Market Size by Type
8.2.1 Asia-Pacific Leuprolide Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Leuprolide Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Leuprolide Market Size by Type (2016-2027)
8.3 Asia-Pacific Leuprolide Market Size by Application
8.3.1 Asia-Pacific Leuprolide Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Leuprolide Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Leuprolide Market Size by Application (2016-2027)
8.4 Asia-Pacific Leuprolide Market Size by Region
8.4.1 Asia-Pacific Leuprolide Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Leuprolide Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Leuprolide Market Size (2016-2027)
9.2 Latin America Leuprolide Market Size by Type
9.2.1 Latin America Leuprolide Market Size by Type (2016-2021)
9.2.2 Latin America Leuprolide Market Size by Type (2022-2027)
9.2.3 Latin America Leuprolide Market Size by Type (2016-2027)
9.3 Latin America Leuprolide Market Size by Application
9.3.1 Latin America Leuprolide Market Size by Application (2016-2021)
9.3.2 Latin America Leuprolide Market Size by Application (2022-2027)
9.3.3 Latin America Leuprolide Market Size by Application (2016-2027)
9.4 Latin America Leuprolide Market Size by Country
9.4.1 Latin America Leuprolide Market Size by Country (2016-2021)
9.4.2 Latin America Leuprolide Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Leuprolide Market Size (2016-2027)
10.2 Middle East & Africa Leuprolide Market Size by Type
10.2.1 Middle East & Africa Leuprolide Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Leuprolide Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Leuprolide Market Size by Type (2016-2027)
10.3 Middle East & Africa Leuprolide Market Size by Application
10.3.1 Middle East & Africa Leuprolide Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Leuprolide Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Leuprolide Market Size by Application (2016-2027)
10.4 Middle East & Africa Leuprolide Market Size by Country
10.4.1 Middle East & Africa Leuprolide Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Leuprolide Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 TOLMAR PHARMACEUTICALS
11.1.1 TOLMAR PHARMACEUTICALS Company Details
11.1.2 TOLMAR PHARMACEUTICALS Business Overview
11.1.3 TOLMAR PHARMACEUTICALS Leuprolide Introduction
11.1.4 TOLMAR PHARMACEUTICALS Revenue in Leuprolide Business (2016-2021)
11.1.5 TOLMAR PHARMACEUTICALS Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Details
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Leuprolide Introduction
11.2.4 Sanofi Revenue in Leuprolide Business (2016-2021)
11.2.5 Sanofi Recent Development
11.3 Teva
11.3.1 Teva Company Details
11.3.2 Teva Business Overview
11.3.3 Teva Leuprolide Introduction
11.3.4 Teva Revenue in Leuprolide Business (2016-2021)
11.3.5 Teva Recent Development
11.4 Sandoz (Novartis)
11.4.1 Sandoz (Novartis) Company Details
11.4.2 Sandoz (Novartis) Business Overview
11.4.3 Sandoz (Novartis) Leuprolide Introduction
11.4.4 Sandoz (Novartis) Revenue in Leuprolide Business (2016-2021)
11.4.5 Sandoz (Novartis) Recent Development
11.5 Sun Pharmaceutical
11.5.1 Sun Pharmaceutical Company Details
11.5.2 Sun Pharmaceutical Business Overview
11.5.3 Sun Pharmaceutical Leuprolide Introduction
11.5.4 Sun Pharmaceutical Revenue in Leuprolide Business (2016-2021)
11.5.5 Sun Pharmaceutical Recent Development
11.6 AbbVie
11.6.1 AbbVie Company Details
11.6.2 AbbVie Business Overview
11.6.3 AbbVie Leuprolide Introduction
11.6.4 AbbVie Revenue in Leuprolide Business (2016-2021)
11.6.5 AbbVie Recent Development
11.7 Bayer
11.7.1 Bayer Company Details
11.7.2 Bayer Business Overview
11.7.3 Bayer Leuprolide Introduction
11.7.4 Bayer Revenue in Leuprolide Business (2016-2021)
11.7.5 Bayer Recent Development
11.8 Takeda
11.8.1 Takeda Company Details
11.8.2 Takeda Business Overview
11.8.3 Takeda Leuprolide Introduction
11.8.4 Takeda Revenue in Leuprolide Business (2016-2021)
11.8.5 Takeda Recent Development
11.9 Beijing Boente Pharmaceutical
11.9.1 Beijing Boente Pharmaceutical Company Details
11.9.2 Beijing Boente Pharmaceutical Business Overview
11.9.3 Beijing Boente Pharmaceutical Leuprolide Introduction
11.9.4 Beijing Boente Pharmaceutical Revenue in Leuprolide Business (2016-2021)
11.9.5 Beijing Boente Pharmaceutical Recent Development
11.10 Livzon Pharmaceutical
11.10.1 Livzon Pharmaceutical Company Details
11.10.2 Livzon Pharmaceutical Business Overview
11.10.3 Livzon Pharmaceutical Leuprolide Introduction
11.10.4 Livzon Pharmaceutical Revenue in Leuprolide Business (2016-2021)
11.10.5 Livzon Pharmaceutical Recent Development
11.11 Selleck
11.11.1 Selleck Company Details
11.11.2 Selleck Business Overview
11.11.3 Selleck Leuprolide Introduction
11.11.4 Selleck Revenue in Leuprolide Business (2016-2021)
11.11.5 Selleck Recent Development
11.12 Hangzhou Peptide Biochemical
11.12.1 Hangzhou Peptide Biochemical Company Details
11.12.2 Hangzhou Peptide Biochemical Business Overview
11.12.3 Hangzhou Peptide Biochemical Leuprolide Introduction
11.12.4 Hangzhou Peptide Biochemical Revenue in Leuprolide Business (2016-2021)
11.12.5 Hangzhou Peptide Biochemical Recent Development
11.13 Chengdu Shenguo Biological Pharmaceutical
11.13.1 Chengdu Shenguo Biological Pharmaceutical Company Details
11.13.2 Chengdu Shenguo Biological Pharmaceutical Business Overview
11.13.3 Chengdu Shenguo Biological Pharmaceutical Leuprolide Introduction
11.13.4 Chengdu Shenguo Biological Pharmaceutical Revenue in Leuprolide Business (2016-2021)
11.13.5 Chengdu Shenguo Biological Pharmaceutical Recent Development
11.14 SciAnda Pharma
11.14.1 SciAnda Pharma Company Details
11.14.2 SciAnda Pharma Business Overview
11.14.3 SciAnda Pharma Leuprolide Introduction
11.14.4 SciAnda Pharma Revenue in Leuprolide Business (2016-2021)
11.14.5 SciAnda Pharma Recent Development
11.15 Daewoong
11.15.1 Daewoong Company Details
11.15.2 Daewoong Business Overview
11.15.3 Daewoong Leuprolide Introduction
11.15.4 Daewoong Revenue in Leuprolide Business (2016-2021)
11.15.5 Daewoong Recent Development
11.16 GP Pharm
11.16.1 GP Pharm Company Details
11.16.2 GP Pharm Business Overview
11.16.3 GP Pharm Leuprolide Introduction
11.16.4 GP Pharm Revenue in Leuprolide Business (2016-2021)
11.16.5 GP Pharm Recent Development
11.17 Enteris BioPharma
11.17.1 Enteris BioPharma Company Details
11.17.2 Enteris BioPharma Business Overview
11.17.3 Enteris BioPharma Leuprolide Introduction
11.17.4 Enteris BioPharma Revenue in Leuprolide Business (2016-2021)
11.17.5 Enteris BioPharma Recent Development
11.18 Chong Kun Dang
11.18.1 Chong Kun Dang Company Details
11.18.2 Chong Kun Dang Business Overview
11.18.3 Chong Kun Dang Leuprolide Introduction
11.18.4 Chong Kun Dang Revenue in Leuprolide Business (2016-2021)
11.18.5 Chong Kun Dang Recent Development
11.18 Leadiant Biosciences
.1 Leadiant Biosciences Company Details
.2 Leadiant Biosciences Business Overview
.3 Leadiant Biosciences Leuprolide Introduction
.4 Leadiant Biosciences Revenue in Leuprolide Business (2016-2021)
.5 Leadiant Biosciences Recent Development
11.20 Hikma Pharmaceuticals
11.20.1 Hikma Pharmaceuticals Company Details
11.20.2 Hikma Pharmaceuticals Business Overview
11.20.3 Hikma Pharmaceuticals Leuprolide Introduction
11.20.4 Hikma Pharmaceuticals Revenue in Leuprolide Business (2016-2021)
11.20.5 Hikma Pharmaceuticals Recent Development
11.21 Lee Pharma
11.21.1 Lee Pharma Company Details
11.21.2 Lee Pharma Business Overview
11.21.3 Lee Pharma Leuprolide Introduction
11.21.4 Lee Pharma Revenue in Leuprolide Business (2016-2021)
11.21.5 Lee Pharma Recent Development
11.22 Hanall
11.22.1 Hanall Company Details
11.22.2 Hanall Business Overview
11.22.3 Hanall Leuprolide Introduction
11.22.4 Hanall Revenue in Leuprolide Business (2016-2021)
11.22.5 Hanall Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Leuprolide Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Subcutaneous
Table 3. Key Players of Topical
Table 4. Global Leuprolide Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Leuprolide Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Leuprolide Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Leuprolide Market Share by Regions (2016-2021)
Table 8. Global Leuprolide Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Leuprolide Market Share by Regions (2022-2027)
Table 10. Leuprolide Market Trends
Table 11. Leuprolide Market Drivers
Table 12. Leuprolide Market Challenges
Table 13. Leuprolide Market Restraints
Table 14. Global Leuprolide Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Leuprolide Market Share by Players (2016-2021)
Table 16. Global Top Leuprolide Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Leuprolide as of 2020)
Table 17. Ranking of Global Top Leuprolide Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Leuprolide Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Leuprolide Product Solution and Service
Table 21. Date of Enter into Leuprolide Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Leuprolide Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Leuprolide Revenue Market Share by Type (2016-2021)
Table 25. Global Leuprolide Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Leuprolide Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Leuprolide Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Leuprolide Revenue Market Share by Application (2016-2021)
Table 29. Global Leuprolide Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Leuprolide Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Leuprolide Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Leuprolide Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Leuprolide Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Leuprolide Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Leuprolide Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Leuprolide Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Leuprolide Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Leuprolide Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Leuprolide Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Leuprolide Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Leuprolide Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Leuprolide Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Leuprolide Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Leuprolide Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Leuprolide Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Leuprolide Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Leuprolide Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Leuprolide Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Leuprolide Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Leuprolide Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Leuprolide Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Leuprolide Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Leuprolide Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Leuprolide Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Leuprolide Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Leuprolide Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Leuprolide Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Leuprolide Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Leuprolide Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Leuprolide Market Size by Country (2022-2027) & (US$ Million)
Table 61. TOLMAR PHARMACEUTICALS Company Details
Table 62. TOLMAR PHARMACEUTICALS Business Overview
Table 63. TOLMAR PHARMACEUTICALS Leuprolide Product
Table 64. TOLMAR PHARMACEUTICALS Revenue in Leuprolide Business (2016-2021) & (US$ Million)
Table 65. TOLMAR PHARMACEUTICALS Recent Development
Table 66. Sanofi Company Details
Table 67. Sanofi Business Overview
Table 68. Sanofi Leuprolide Product
Table 69. Sanofi Revenue in Leuprolide Business (2016-2021) & (US$ Million)
Table 70. Sanofi Recent Development
Table 71. Teva Company Details
Table 72. Teva Business Overview
Table 73. Teva Leuprolide Product
Table 74. Teva Revenue in Leuprolide Business (2016-2021) & (US$ Million)
Table 75. Teva Recent Development
Table 76. Sandoz (Novartis) Company Details
Table 77. Sandoz (Novartis) Business Overview
Table 78. Sandoz (Novartis) Leuprolide Product
Table 79. Sandoz (Novartis) Revenue in Leuprolide Business (2016-2021) & (US$ Million)
Table 80. Sandoz (Novartis) Recent Development
Table 81. Sun Pharmaceutical Company Details
Table 82. Sun Pharmaceutical Business Overview
Table 83. Sun Pharmaceutical Leuprolide Product
Table 84. Sun Pharmaceutical Revenue in Leuprolide Business (2016-2021) & (US$ Million)
Table 85. Sun Pharmaceutical Recent Development
Table 86. AbbVie Company Details
Table 87. AbbVie Business Overview
Table 88. AbbVie Leuprolide Product
Table 89. AbbVie Revenue in Leuprolide Business (2016-2021) & (US$ Million)
Table 90. AbbVie Recent Development
Table 91. Bayer Company Details
Table 92. Bayer Business Overview
Table 93. Bayer Leuprolide Product
Table 94. Bayer Revenue in Leuprolide Business (2016-2021) & (US$ Million)
Table 95. Bayer Recent Development
Table 96. Takeda Company Details
Table 97. Takeda Business Overview
Table 98. Takeda Revenue in Leuprolide Business (2016-2021) & (US$ Million)
Table 99. Takeda Recent Development
Table 100. Beijing Boente Pharmaceutical Company Details
Table 101. Beijing Boente Pharmaceutical Business Overview
Table 102. Beijing Boente Pharmaceutical Leuprolide Product
Table 103. Beijing Boente Pharmaceutical Revenue in Leuprolide Business (2016-2021) & (US$ Million)
Table 104. Beijing Boente Pharmaceutical Recent Development
Table 105. Livzon Pharmaceutical Company Details
Table 106. Livzon Pharmaceutical Business Overview
Table 107. Livzon Pharmaceutical Leuprolide Product
Table 108. Livzon Pharmaceutical Revenue in Leuprolide Business (2016-2021) & (US$ Million)
Table 109. Livzon Pharmaceutical Recent Development
Table 110. Selleck Company Details
Table 111. Selleck Business Overview
Table 112. Selleck Leuprolide Product
Table 113. Selleck Revenue in Leuprolide Business (2016-2021) & (US$ Million)
Table 114. Selleck Recent Development
Table 115. Hangzhou Peptide Biochemical Company Details
Table 116. Hangzhou Peptide Biochemical Business Overview
Table 117. Hangzhou Peptide Biochemical Leuprolide Product
Table 118. Hangzhou Peptide Biochemical Revenue in Leuprolide Business (2016-2021) & (US$ Million)
Table 119. Hangzhou Peptide Biochemical Recent Development
Table 120. Chengdu Shenguo Biological Pharmaceutical Company Details
Table 121. Chengdu Shenguo Biological Pharmaceutical Business Overview
Table 122. Chengdu Shenguo Biological Pharmaceutical Leuprolide Product
Table 123. Chengdu Shenguo Biological Pharmaceutical Revenue in Leuprolide Business (2016-2021) & (US$ Million)
Table 124. Chengdu Shenguo Biological Pharmaceutical Recent Development
Table 125. SciAnda Pharma Company Details
Table 126. SciAnda Pharma Business Overview
Table 127. SciAnda Pharma Leuprolide Product
Table 128. SciAnda Pharma Revenue in Leuprolide Business (2016-2021) & (US$ Million)
Table 129. SciAnda Pharma Recent Development
Table 130. Daewoong Company Details
Table 131. Daewoong Business Overview
Table 132. Daewoong Leuprolide Product
Table 133. Daewoong Revenue in Leuprolide Business (2016-2021) & (US$ Million)
Table 134. Daewoong Recent Development
Table 135. GP Pharm Company Details
Table 136. GP Pharm Business Overview
Table 137. GP Pharm Leuprolide Product
Table 138. GP Pharm Revenue in Leuprolide Business (2016-2021) & (US$ Million)
Table 139. GP Pharm Recent Development
Table 140. Enteris BioPharma Company Details
Table 141. Enteris BioPharma Business Overview
Table 142. Enteris BioPharma Leuprolide Product
Table 143. Enteris BioPharma Revenue in Leuprolide Business (2016-2021) & (US$ Million)
Table 144. Enteris BioPharma Recent Development
Table 145. Chong Kun Dang Company Details
Table 146. Chong Kun Dang Business Overview
Table 147. Chong Kun Dang Leuprolide Product
Table 148. Chong Kun Dang Revenue in Leuprolide Business (2016-2021) & (US$ Million)
Table 149. Chong Kun Dang Recent Development
Table 150. Leadiant Biosciences Company Details
Table 151. Leadiant Biosciences Business Overview
Table 152. Leadiant Biosciences Leuprolide Product
Table 153. Leadiant Biosciences Revenue in Leuprolide Business (2016-2021) & (US$ Million)
Table 154. Leadiant Biosciences Recent Development
Table 155. Hikma Pharmaceuticals Company Details
Table 156. Hikma Pharmaceuticals Business Overview
Table 157. Hikma Pharmaceuticals Leuprolide Product
Table 158. Hikma Pharmaceuticals Revenue in Leuprolide Business (2016-2021) & (US$ Million)
Table 159. Hikma Pharmaceuticals Recent Development
Table 160. Lee Pharma Company Details
Table 161. Lee Pharma Business Overview
Table 162. Lee Pharma Leuprolide Product
Table 163. Lee Pharma Revenue in Leuprolide Business (2016-2021) & (US$ Million)
Table 164. Lee Pharma Recent Development
Table 165. Hanall Company Details
Table 166. Hanall Business Overview
Table 167. Hanall Leuprolide Product
Table 168. Hanall Revenue in Leuprolide Business (2016-2021) & (US$ Million)
Table 169. Hanall Recent Development
Table 170. Research Programs/Design for This Report
Table 171. Key Data Information from Secondary Sources
Table 172. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Leuprolide Market Share by Type: 2020 VS 2027
Figure 2. Subcutaneous Features
Figure 3. Topical Features
Figure 4. Global Leuprolide Market Share by Application: 2020 VS 2027
Figure 5. Breast Cancer Case Studies
Figure 6. Endometriosis Case Studies
Figure 7. Precocious Puberty Case Studies
Figure 8. Prostate Cancer Case Studies
Figure 9. Uterine Fibrosis Case Studies
Figure 10. Other Case Studies
Figure 11. Leuprolide Report Years Considered
Figure 12. Global Leuprolide Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Leuprolide Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Leuprolide Market Share by Regions: 2020 VS 2027
Figure 15. Global Leuprolide Market Share by Regions (2022-2027)
Figure 16. Global Leuprolide Market Share by Players in 2020
Figure 17. Global Top Leuprolide Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Leuprolide as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Leuprolide Revenue in 2020
Figure 19. Global Leuprolide Revenue Market Share by Type (2016-2021)
Figure 20. Global Leuprolide Revenue Market Share by Type (2022-2027)
Figure 21. North America Leuprolide Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Leuprolide Market Share by Type (2016-2027)
Figure 23. North America Leuprolide Market Share by Application (2016-2027)
Figure 24. North America Leuprolide Market Share by Country (2016-2027)
Figure 25. United States Leuprolide Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Leuprolide Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Leuprolide Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Leuprolide Market Share by Type (2016-2027)
Figure 29. Europe Leuprolide Market Share by Application (2016-2027)
Figure 30. Europe Leuprolide Market Share by Country (2016-2027)
Figure 31. Germany Leuprolide Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Leuprolide Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Leuprolide Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Leuprolide Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Leuprolide Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Leuprolide Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Leuprolide Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Leuprolide Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Leuprolide Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Leuprolide Market Share by Region (2016-2027)
Figure 41. China Leuprolide Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Leuprolide Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Leuprolide Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Leuprolide Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Leuprolide Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Leuprolide Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Leuprolide Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Leuprolide Market Share by Type (2016-2027)
Figure 49. Latin America Leuprolide Market Share by Application (2016-2027)
Figure 50. Latin America Leuprolide Market Share by Country (2016-2027)
Figure 51. Mexico Leuprolide Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Leuprolide Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Leuprolide Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Leuprolide Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Leuprolide Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Leuprolide Market Share by Country (2016-2027)
Figure 57. Turkey Leuprolide Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Leuprolide Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Leuprolide Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. TOLMAR PHARMACEUTICALS Revenue Growth Rate in Leuprolide Business (2016-2021)
Figure 61. Sanofi Revenue Growth Rate in Leuprolide Business (2016-2021)
Figure 62. Teva Revenue Growth Rate in Leuprolide Business (2016-2021)
Figure 63. Sandoz (Novartis) Revenue Growth Rate in Leuprolide Business (2016-2021)
Figure 64. Sun Pharmaceutical Revenue Growth Rate in Leuprolide Business (2016-2021)
Figure 65. AbbVie Revenue Growth Rate in Leuprolide Business (2016-2021)
Figure 66. Bayer Revenue Growth Rate in Leuprolide Business (2016-2021)
Figure 67. Takeda Revenue Growth Rate in Leuprolide Business (2016-2021)
Figure 68. Beijing Boente Pharmaceutical Revenue Growth Rate in Leuprolide Business (2016-2021)
Figure 69. Livzon Pharmaceutical Revenue Growth Rate in Leuprolide Business (2016-2021)
Figure 70. Selleck Revenue Growth Rate in Leuprolide Business (2016-2021)
Figure 71. Hangzhou Peptide Biochemical Revenue Growth Rate in Leuprolide Business (2016-2021)
Figure 72. Chengdu Shenguo Biological Pharmaceutical Revenue Growth Rate in Leuprolide Business (2016-2021)
Figure 73. SciAnda Pharma Revenue Growth Rate in Leuprolide Business (2016-2021)
Figure 74. Daewoong Revenue Growth Rate in Leuprolide Business (2016-2021)
Figure 75. GP Pharm Revenue Growth Rate in Leuprolide Business (2016-2021)
Figure 76. Enteris BioPharma Revenue Growth Rate in Leuprolide Business (2016-2021)
Figure 77. Chong Kun Dang Revenue Growth Rate in Leuprolide Business (2016-2021)
Figure 78. Leadiant Biosciences Revenue Growth Rate in Leuprolide Business (2016-2021)
Figure 79. Hikma Pharmaceuticals Revenue Growth Rate in Leuprolide Business (2016-2021)
Figure 80. Lee Pharma Revenue Growth Rate in Leuprolide Business (2016-2021)
Figure 81. Hanall Revenue Growth Rate in Leuprolide Business (2016-2021)
Figure 82. Bottom-up and Top-down Approaches for This Report
Figure 83. Data Triangulation
Figure 84. Key Executives Interviewed
世界の前立腺がん治療市場規模・現状・予測（2021年-2027年） Prostate cancer is the most common cancer among men, the key risk factors for prostate cancer development is being old age, genetic, obesity and race. Market Analysis and Insights: Global Prostate Cancer Treatment Market The global Prostate Cancer Treatment market size is projected to reach US$ XX m…- 世界の前立腺がん治療市場規模・現状・予測（2021年-2027年） Prostate cancer is the most common cancer among men, the key risk factors for prostate cancer development is being old age, genetic, obesity and race. Market Analysis and Insights: Global Prostate Cancer Treatment Market The global Prostate Cancer Treatment market size is projected to reach US$ XX m…
- 世界の前立腺がんバイオマーカー市場規模・現状・予測（2021年-2027年） Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. The prostate cancer biomarker market is expected to witness a fast growth owing to rising prevalence of prostate cancer. Market Analysis and Insights: Global Prostate Cancer Biomarker Market The gl…
- 世界の前立腺がん検査市場規模・現状・予測（2021年-2027年） Prostate cancer testing refers to the tests conducted for the detection, localization, grading, and staging of prostate carcinoma. The currently established methods of prostate cancer detection include digital rectal examination (DRE), serum prostate-specific antigen (PSA) tests, and transrectal ult…
- 世界の前立腺がん治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Prostate Cancer Therapeutics Market The global Prostate Cancer Therapeutics market size is projected to reach US$ 9677.3 million by 2026, from US$ 7420 million in 2019, at a CAGR of 3.8% during 2021-2026. With industry-standard accuracy in analysis and high data …